<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03906149</url>
  </required_header>
  <id_info>
    <org_study_id>18-8440-BO</org_study_id>
    <nct_id>NCT03906149</nct_id>
  </id_info>
  <brief_title>Whole-body Hyperthermia for Moderate to Severe Depressive Disorder</brief_title>
  <acronym>HYPE2</acronym>
  <official_title>Whole-body Hyperthermia for Moderate to Severe Depressive Disorder - a Randomized Controlled Tiral</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universität Duisburg-Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universität Duisburg-Essen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to investigate the effectiveness of whole-body hyperthermia
      in addition to standard medical care in comparison to standard medical care alone on
      depressive symptom severity in patients with moderate to severe depressive disorder.

      Secondary aims included further quality of life outcomes, immunological parameters, and
      tolerability/safety of the hyperthermia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Depression Severity: clinician-rated</measure>
    <time_frame>week 6</time_frame>
    <description>Hamilton Rating Scale for Depression (HAMD-17)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depression Severity: clinician-rated</measure>
    <time_frame>week 1</time_frame>
    <description>Hamilton Rating Scale for Depression (HAMD-17)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression Severity: clinician-rated</measure>
    <time_frame>week 3</time_frame>
    <description>Hamilton Rating Scale for Depression (HAMD-17)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression Severity: clinician-rated</measure>
    <time_frame>week 12</time_frame>
    <description>Hamilton Rating Scale for Depression (HAMD-17)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression Severity: patient-rated</measure>
    <time_frame>week 1</time_frame>
    <description>Beck Depression Inventory II (BDI-II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression Severity: patient-rated</measure>
    <time_frame>week 3</time_frame>
    <description>Beck Depression Inventory II (BDI-II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression Severity: patient-rated</measure>
    <time_frame>week 6</time_frame>
    <description>Beck Depression Inventory II (BDI-II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression Severity: patient-rated</measure>
    <time_frame>week 12</time_frame>
    <description>Beck Depression Inventory II (BDI-II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global improvement: clinician-rated</measure>
    <time_frame>week 1</time_frame>
    <description>Clinical Global Impression Scale (CGI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global improvement: clinician-rated</measure>
    <time_frame>week 3</time_frame>
    <description>Clinical Global Impression Scale (CGI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global improvement: clinician-rated</measure>
    <time_frame>week 6</time_frame>
    <description>Clinical Global Impression Scale (CGI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global improvement: clinician-rated</measure>
    <time_frame>week 12</time_frame>
    <description>Clinical Global Impression Scale (CGI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Functioning: clinician-rated</measure>
    <time_frame>week 1</time_frame>
    <description>Global Assessment of Functioning Scale (GAF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Functioning: clinician-rated</measure>
    <time_frame>week 3</time_frame>
    <description>Global Assessment of Functioning Scale (GAF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Functioning: clinician-rated</measure>
    <time_frame>week 6</time_frame>
    <description>Global Assessment of Functioning Scale (GAF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Functioning: clinician-rated</measure>
    <time_frame>week 12</time_frame>
    <description>Global Assessment of Functioning Scale (GAF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue: patient-rated</measure>
    <time_frame>week 1</time_frame>
    <description>Multidimensional Fatigue Inventory (MFI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue: patient-rated</measure>
    <time_frame>week 3</time_frame>
    <description>Multidimensional Fatigue Inventory (MFI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue: patient-rated</measure>
    <time_frame>week 6</time_frame>
    <description>Multidimensional Fatigue Inventory (MFI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue: patient-rated</measure>
    <time_frame>week 12</time_frame>
    <description>Multidimensional Fatigue Inventory (MFI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress: patient-rated</measure>
    <time_frame>week 1</time_frame>
    <description>Perceived Stress-Scale (PSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress: patient-rated</measure>
    <time_frame>week 3</time_frame>
    <description>Perceived Stress-Scale (PSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress: patient-rated</measure>
    <time_frame>week 6</time_frame>
    <description>Perceived Stress-Scale (PSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress: patient-rated</measure>
    <time_frame>week 12</time_frame>
    <description>Perceived Stress-Scale (PSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life: patient-rated</measure>
    <time_frame>week 1</time_frame>
    <description>Short Form Health Survey (SF-12)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life: patient-rated</measure>
    <time_frame>week 3</time_frame>
    <description>Short Form Health Survey (SF-12)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life: patient-rated</measure>
    <time_frame>week 6</time_frame>
    <description>Short Form Health Survey (SF-12)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life: patient-rated</measure>
    <time_frame>week 12</time_frame>
    <description>Short Form Health Survey (SF-12)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: interleukin 2</measure>
    <time_frame>week 1</time_frame>
    <description>IL-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: interleukin 2</measure>
    <time_frame>week 3</time_frame>
    <description>IL-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: interleukin 2</measure>
    <time_frame>week 6</time_frame>
    <description>IL-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: interleukin 2</measure>
    <time_frame>week 12</time_frame>
    <description>IL-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: interleukin 6</measure>
    <time_frame>week 1</time_frame>
    <description>IL-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: interleukin 6</measure>
    <time_frame>week 3</time_frame>
    <description>IL-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: interleukin 6</measure>
    <time_frame>week 6</time_frame>
    <description>IL-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: interleukin 6</measure>
    <time_frame>week 12</time_frame>
    <description>IL-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: interleukin 10</measure>
    <time_frame>week 1</time_frame>
    <description>IL-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: interleukin 10</measure>
    <time_frame>week 3</time_frame>
    <description>IL-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: interleukin 10</measure>
    <time_frame>week 6</time_frame>
    <description>IL-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: interleukin 10</measure>
    <time_frame>week 12</time_frame>
    <description>IL-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: tumor necrosis factor-alpha</measure>
    <time_frame>week 1</time_frame>
    <description>TNF-alpha</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: tumor necrosis factor-alpha</measure>
    <time_frame>week 3</time_frame>
    <description>TNF-alpha</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: tumor necrosis factor-alpha</measure>
    <time_frame>week 6</time_frame>
    <description>TNF-alpha</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: tumor necrosis factor-alpha</measure>
    <time_frame>week 12</time_frame>
    <description>TNF-alpha</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: high-sensitivity C-reactive Protein</measure>
    <time_frame>week 1</time_frame>
    <description>hs-CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: high-sensitivity C-reactive Protein</measure>
    <time_frame>week 3</time_frame>
    <description>hs-CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: high-sensitivity C-reactive Protein</measure>
    <time_frame>week 6</time_frame>
    <description>hs-CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: high-sensitivity C-reactive Protein</measure>
    <time_frame>week 12</time_frame>
    <description>hs-CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: soluble intercellular adhesion molecule-1</measure>
    <time_frame>week 1</time_frame>
    <description>sICAM-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: soluble intercellular adhesion molecule-1</measure>
    <time_frame>week 3</time_frame>
    <description>sICAM-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: soluble intercellular adhesion molecule-1</measure>
    <time_frame>week 6</time_frame>
    <description>sICAM-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: soluble intercellular adhesion molecule-1</measure>
    <time_frame>week 12</time_frame>
    <description>sICAM-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: tryptophan</measure>
    <time_frame>week 1</time_frame>
    <description>tryptophan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: tryptophan</measure>
    <time_frame>week 3</time_frame>
    <description>tryptophan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: tryptophan</measure>
    <time_frame>week 6</time_frame>
    <description>tryptophan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: tryptophan</measure>
    <time_frame>week 12</time_frame>
    <description>tryptophan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: kynurenine</measure>
    <time_frame>week 1</time_frame>
    <description>kynurenine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: kynurenine</measure>
    <time_frame>week 3</time_frame>
    <description>kynurenine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: kynurenine</measure>
    <time_frame>week 6</time_frame>
    <description>kynurenine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: kynurenine</measure>
    <time_frame>week 12</time_frame>
    <description>kynurenine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: neopterin</measure>
    <time_frame>week 1</time_frame>
    <description>neopterin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: neopterin</measure>
    <time_frame>week 3</time_frame>
    <description>neopterin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: neopterin</measure>
    <time_frame>week 6</time_frame>
    <description>neopterin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: neopterin</measure>
    <time_frame>week 12</time_frame>
    <description>neopterin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>week 1</time_frame>
    <description>Number of patients with adverse events, total number and type of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>week 3</time_frame>
    <description>Number of patients with adverse events, total number and type of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>week 6</time_frame>
    <description>Number of patients with adverse events, total number and type of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>week 12</time_frame>
    <description>Number of patients with adverse events, total number and type of adverse events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Treatment Expectations</measure>
    <time_frame>week -1</time_frame>
    <description>Treatment Credibility Scale (TCS)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Depression, Unipolar</condition>
  <arm_group>
    <arm_group_label>Whole-body hyperthermia + standard medical care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Whole-body hyperthermia will be applied 2 times during 4 weeks in addition to guideline-based standard medical care for depression (anti-depressive drug treatment in combination with psychotherapy). At week 6, the primary outcome will be assessed. The participants will be reassessed 12 weeks after the start of the treatment with whole-body hyperthermia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard medical care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will maintain standard medical care for depression (anti-depressive drug treatment in combination with psychotherapy). At week 6, the primary outcome will be assessed. The participants will be reassessed 12 weeks after randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Whole-body hyperthermia + standard medical care</intervention_name>
    <description>Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization) in addition to standard medical care. The hyperthermia will be applied using Heckel-HT3000 MPIIb. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.</description>
    <arm_group_label>Whole-body hyperthermia + standard medical care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Standard medical care</intervention_name>
    <description>Standard medical care included guideline-based anti-depressive drug treatment in combination with psychotherapy. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.</description>
    <arm_group_label>Standard medical care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unipolar depression (diagnosed according to the DSM-IV)

          -  Moderate depression: 17-23 points on the HAMD-17 or severe depression: ≥24 points on
             the HAMD-17

        Exclusion Criteria:

          -  Participants who did not respond to prior antidepressant drug treatment,
             electroconvulsive therapy, or sleep deprivation (therapy-resistant depression)

          -  Acute suicidality

          -  Prior treatment with whole-body hyperthermia

          -  Contraindications to hyperthermia treatment: acute or feverish infections, severe
             cardiovascular diseases (e.g. angina pectoris, heart failure, thrombosis, bleeding
             diathesis), severe gastrointestinal diseases (e.g. renal insufficiency, hepatitis,
             liver cirrhosis, peptic ulcer), severe neurological diseases (e.g. epilepsy, multiple
             sclerosis, cerebrovascular malformations or brain tumors), severe endocrine diseases
             (e.g. hyperthyroidism), or oncological diseases without remission

          -  Participants taking anti-inflammatory or immunosuppressive drugs

          -  Participants with severe psychiatric comorbidities (e.g. schizophrenia,
             schizoaffective disorder, bipolar disorder, dementia, ADHD, obsessive-compulsive
             disorder, PTSD, alcohol or drug addiction)

          -  Women during pregnancy and breastfeeding

          -  Lack of ability to consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustav Dobos, Prof. MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, Faculty of Medicine, University of Duisburg-Essen, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Holger Cramer, PhD</last_name>
    <phone>+4920117425015</phone>
    <email>h.cramer@kem-med.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heidemarie Haller, PhD</last_name>
    <phone>+4920117425044</phone>
    <email>h.haller@kem-med.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Psychiatry, Psychotherapy and Addiciton Medicine, Kliniken Essen-Mitte</name>
      <address>
        <city>Essen</city>
        <zip>45276</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Schäfer, Prof. MD</last_name>
      <phone>+4920117430001</phone>
      <email>m.schaefer@kem-med.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 4, 2019</study_first_submitted>
  <study_first_submitted_qc>April 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2019</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universität Duisburg-Essen</investigator_affiliation>
    <investigator_full_name>Holger Cramer</investigator_full_name>
    <investigator_title>Research Director</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Hyperthermia</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fever</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

